WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine. The following distinguished investigators join Dr. Gabriel N. Hortobagyi, MD, FACP ( University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD ( Indiana University School of Medicine Melvin and Bren Simon Cancer Center), and Dr. Hope S. Rugo, MD ( University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center) on the SAB:
Dr. Keith L. Knutson. PhD Associate Professor, Department of Immunology Mayo Clinic
Dr. Knutson's current interests and research focus on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. His laboratory research on cancer vaccines focuses on augmenting CD4 helper T cell immunity using peptide epitopes. These vaccine strategies are aimed at preventing patients from relapsing after optimal conventional therapies. Adoptive T cell therapy is also being examined, a strategy that involves infusing high numbers of T cells into patients with active bulky malignancy.
In addition to his research, Dr. Knutson participates in and chairs several study sections; is Director of the Mayo Clinic Cancer Center Immunology and Immunotherapy Program; Co-director, Mayo Clinic Immune Monitoring Core; and Director, Ovarian Cancer Immunotherapy Program at Mayo Clinic.Dr. Knutson received his PhD from the University of Georgia in Physiology and Pharmacology in 1995 and completed two post-doctoral fellowships in immunology: one at the University of British Columbia; and the other at the University of Washington. He was a 2004 recipient of a Howard Temin Award from the National Cancer Institute. Dr. James J. Mule Moffitt Cancer Center Dr. Mule is the Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV